Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Semin Thorac Cardiovasc Surg. 2022 Spring;34(1):300-308. doi: 10.1053/j.semtcvs.2021.01.002. Epub 2021 Jan 12.
We evaluated the feasibility of video-assisted thoracoscopic surgery (VATS) following neoadjuvant concurrent chemoradiotherapy (nCCRT) for N2 non-small-cell lung cancer (NSCLC). We retrospectively reviewed patients with clinical N2 NSCLC who underwent lobectomy and lymph node dissection after nCCRT. The patients were matched using a propensity score based on age, sex, pulmonary function test, histologic type, clinical T factor, and method of N-staging. A total of 385 patients were enrolled between June 2012 and July 2017 (35 VATS, 350 open). After propensity matching (31 VATS, 112 open), the VATS group showed a significantly lower major complication rate (≥ grade II Clavien-Dindo classification; 9.7% vs 30.4%, P = 0.036). No significant differences were found between 2 group of 5-year survival rates (77.1% for the VATS group, 59.9% for the open group; P = 0.276) and recurrence-free survival rates (66.3% for the VATS group, 54.6% for the open group; P = 0.354). In multivariable analysis, VATS did not affect overall survival and recurrence-free survival. VATS was comparable to open thoracotomy in patients with clinical N2 NSCLC after nCCRT without compromising oncologic efficacy.
我们评估了新辅助同步放化疗(nCCRT)后行电视辅助胸腔镜手术(VATS)治疗 N2 非小细胞肺癌(NSCLC)的可行性。我们回顾性分析了 nCCRT 后行肺叶切除术和淋巴结清扫术的临床 N2 NSCLC 患者。通过基于年龄、性别、肺功能检查、组织学类型、临床 T 因素和 N 分期方法的倾向评分匹配患者。共纳入 2012 年 6 月至 2017 年 7 月间的 385 例患者(35 例 VATS,350 例开胸)。经过倾向评分匹配(31 例 VATS,112 例开胸)后,VATS 组的主要并发症发生率(≥Clavien-Dindo 分级Ⅱ级;9.7% vs 30.4%,P=0.036)显著降低。两组患者的 5 年生存率(VATS 组 77.1%,开胸组 59.9%;P=0.276)和无复发生存率(VATS 组 66.3%,开胸组 54.6%;P=0.354)无显著差异。多变量分析显示,VATS 不影响总生存和无复发生存。在 nCCRT 后,VATS 与开胸手术在临床 N2 NSCLC 患者中具有可比性,而不会影响肿瘤学疗效。